Abstract
The diagnostic yield of genetic testing for pediatric sensorineural hearing loss (SNHL) has remained at around 40% for over a decade despite newly discovered causative genes and the expanded use of exome sequencing (ES). This stagnation may be due to (1) a focus on coding regions of the genome and (2) an inability to resolve variants in complex genomic regions due to reliance on short-read sequencing technologies. Short-read genome sequencing (srGS) and long-read genome sequencing (lrGS) both provide exonic single nucleotide variant (SNV) and small indel detection at the same sensitivity as ES, but also evaluate intronic regions. lrGS provides improved resolution for structural variants (SV) and repetitive genomic regions. We sought to investigate the potential utility of lrGS in the diagnostic evaluation of a small cohort of patients with SNHL of unknown etiology after ES and srGS. 19 pediatric patients with SNHL underwent lrGS via PacBio SMRT sequencing. Sequencing data were processed using the PacBio WGS variant pipeline. The diagnostic yield for this lrGS cohort was 4/19 (21%). Relevant variants detected only with lrGS included a hemizygous deletion in trans with a missense variant in an area of high genomic homology (OTOA) and two single nucleotide loss-of-function variants in trans to a known copy-number-loss for a gene with a highly homologous pseudogene (STRC). A complex inversion was identified in the MITF gene which was also identified on post-hoc analysis by srGS. LrGS provides improved resolution for complex genomic structural variation which may increase diagnostic yield for genetic pediatric SNHL, and, potentially, rare disease more broadly.
Competing Interest Statement
AES is the principal investigator of an investigator initiated clinical trial, Genetic Newborn Hearing Screening, funded by Akouos/Eli Lilly; the site principal investigator of the sponsored Phase I/II clinical trial OTOF gene therapy with Akous/Eli Lilly; and on the advisory board without compensation for Akous/Eli Lilly and Decibel/Akous. WJR, CN, JMH, CTS, CF, EML, CL, and MAE are employees and shareholders of PacBio. The other authors have no conflicts of interest to declare.
Funding Statement
This study was funded by NIDCD K08 DC19716 and by Escuchar Sin Fronteras Foundation to AES with support from the Boston Children's Hospital Rare Disease Cohort Initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Boston Children's Hospital gave ethical approval for this work. This work was approved under Boston Children's Hospital IRB protocols P00035179 and P00031494.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Most data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.
